---

Lancet Oncology

ルーム内検索
全23件   1  2 次の20件>>
ID
トピック名
閲覧/投稿
最新投稿
作成
352 【臨床試験】Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. 229 / 0
2016-10-17
KMF CRC
351 【臨床試験】Carfilzomib therapy improves quality of life in multiple myeloma. 218 / 0
2016-10-17
KMF CRC
350 【レビュー】International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. 177 / 0
2016-10-17
KMF CRC
349 【臨床試験】Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. 217 / 0
2016-10-17
KMF CRC
348 【臨床試験】Multiple myeloma--translation of trial results into reality. 186 / 0
2016-10-17
KMF CRC
347 【臨床研究】Ixazomib for multiple myeloma. 190 / 0
2016-10-17
KMF CRC
346 【臨床研究】Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. 189 / 0
2016-10-17
KMF CRC
345 【臨床研究】Dual inhibition of oncogenic targets for B-cell malignancies. 213 / 0
2016-10-17
KMF CRC
344 【臨床研究】Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. 196 / 0
2016-10-17
KMF CRC
343 【臨床研究】Daratumumab in multiple myeloma. 192 / 0
2016-10-17
KMF CRC
342 【コメント】Clonal heterogeneity in plasma cell myeloma. 160 / 0
2016-10-17
KMF CRC
341 【レビュー】NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments. 166 / 0
2016-10-17
KMF CRC
340 【臨床研究】Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. 241 / 0
2016-10-17
KMF CRC
337 【臨床研究】Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. 171 / 0
2016-10-17
KMF CRC
336 【レビュー】Continued role for ASCT in multiple myeloma. 157 / 0
2016-10-17
KMF CRC
174 【臨床研究】Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. 581 / 0
2015-02-24
KMF CRC
172 【臨床研究】Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. 557 / 0
2015-02-23
KMF CRC
171 【レビュー】International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 447 / 0
2015-02-23
KMF CRC
161 【臨床研究】High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l 865 / 0
2014-08-09
KMF CRC
140 【臨床研究】Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data 444 / 0
2014-03-29
KMF CRC
全23件   1  2 次の20件>>